Zoryve cream 0.15% improves atopic dermatitis across diverse skin types

Zoryve cream 0.15% continues to show that it can provide clinical improvement to patients with atopic dermatitis, according to a press release.
Presented at the European Academy of Dermatology & Venereology Congress 2024, new phase 3 results from the INTEGUMENT-1 and -2 trials show that Zoryve (roflumilast, Arcutis) cream 0.15% can alleviate atopic dermatitis in all skin types.
“We know that the clinical presentation of atopic dermatitis (AD) can vary by race, ethnicity and Fitzpatrick skin type,” Vimal H. Prajapati, FRCPC, DABD, clinical associate professor at the

Zoryve cream 0.15% continues to show that it can provide clinical improvement to patients with atopic dermatitis, according to a press release.
Presented at the European Academy of Dermatology & Venereology Congress 2024, new phase 3 results from the INTEGUMENT-1 and -2 trials show that Zoryve (roflumilast, Arcutis) cream 0.15% can alleviate atopic dermatitis in all skin types.
“We know that the clinical presentation of atopic dermatitis (AD) can vary by race, ethnicity and Fitzpatrick skin type,” Vimal H. Prajapati, FRCPC, DABD, clinical associate professor at the